Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clinically achievable drug levels. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, inc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236248/
https://ncbi.nlm.nih.gov/pubmed/21482694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-1044
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items